van Broekhoven, Amber
Eikelboom, John W.
Nidorf, Stefan M.
Mosterd, Arend
Cornel, Jan H. https://orcid.org/0000-0002-1006-2112
,
Funding for this research was provided by:
National Health Medical Research Council of Australia
Sir Charles Gairdner Research Advisory Committee
Withering Foundation the Netherlands
Netherlands Heart Foundation
Netherlands Organization for Health Research and Development
Teva, Disphar, and Tiofarma in the Netherlands
Article History
Accepted: 28 June 2023
First Online: 20 July 2023
Declarations
:
: This work was supported by the National Health Medical Research Council of Australia, a grant from the Sir Charles Gairdner Research Advisory Committee, the Withering Foundation the Netherlands, the Netherlands Heart Foundation, the Netherlands Organization for Health Research and Development, and a consortium of Teva, Disphar, and Tiofarma in the Netherlands.
: AvB and SMN have nothing to disclose. JWE reports consulting/honoraria support from AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myer-Squibb, Daiichi-Sankyo, Eli Lilly, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis, Servier and grants and/or in-kind support from AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myer-Squibb, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis. JHC reports membership of advisory boards with Amgen, AstraZeneca.
: The data underlying this article will be shared on reasonable request to the Steering Committee via A.Mosterd@meandermc.nl.
: The trial protocol was approved by a central institutional review board in each participating country. Trial registration: ACTRN12614000093684, 24 January 2014.
: All participants gave their informed consent to have blood drawn at the close-out visit at the end of the LoDoCo2 trial.
: Not applicable.
: Not applicable.
: All authors contributed to the conception of the strategy. The first draft of the manuscript was written by AvB and SMN and all authors critically reviewed and approved the final manuscript.